ArticlePDF Available

The Therapeutic Role of Ursodeoxycholic Acid in Digestive Diseases

Authors:

Abstract and Figures

Ursodeoxycholic acid (UDCA) makes up a small portion of the naturally occurring bile acid pool in humans, and the drug is effective in several diseases. The mechanism of action involves the displacement of more toxic endogenous bile acids, direct protection of hepatocytes against apoptosis, and stimulation of endogenous secretion of bile to alleviate cholestasis. The use of UDCA has been studied extensively in primary biliary cirrhosis and cholelithiasis and there is evidence for its use in both diseases. There is also evidence against the use of UDCA in primary sclerosing cholangitis (PSC). Several potential uses of UDCA warrant further investigation after initial studies have shown promise including treatment for microlithiasis, intrahepatic cholestasis of pregnancy, total parenteral nutrition, chemoprophylaxis of colorectal cancer in patients with ulcerative colitis and PSC, viral hepatitis, and in bone marrow transplantation. Ursodeoxycholic acid is generally well tolerated with few adverse events, though minor weight gain is a common side effect.
Content may be subject to copyright.
San Lucas Medical, LLC
The Therapeutic Role of Ursodeoxycholic Acid in Digestive
Diseases
Anthony Gamboa, Chenlu Tian, Julia Massaad, Preeti Reshamwala and Qiang Cai
Affiliation: Division of Digestive Diseases, School of Medicine, Emory University, Atlanta, GA, USA
ABSTRACT
Ursodeoxycholic acid (UDCA) makes up a small portion of the naturally occurring bile acid pool in humans, and the drug is effective in
several diseases. The mechanism of action involves the displacement of more toxic endogenous bile acids, direct protection of hepatocytes
against apoptosis, and stimulation of endogenous secretion of bile to alleviate cholestasis. The use of UDCA has been studied extensively in
primary biliary cirrhosis and cholelithiasis and there is evidence for its use in both diseases. There is also evidence against the use of UDCA in
primary sclerosing cholangitis (PSC). Several potential uses of UDCA warrant further investigation after initial studies have shown promise
including treatment for microlithiasis, intrahepatic cholestasis of pregnancy, total parenteral nutrition, chemoprophylaxis of colorectal cancer
in patients with ulcerative colitis and PSC, viral hepatitis, and in bone marrow transplantation. Ursodeoxycholic acid is generally well tolerated
with few adverse events, though minor weight gain is a common side effect.
Keywords: Ursodeoxycholic acid, primary biliary cirrhosis, primary sclerosing cholangitis, cholelithiasis, microlithiasis
Correspondence: Qiang Cai, Division of Digestive Diseases, School of Medicine, Emory University, 1365 Clifton Road, B1262, Atlanta, GA
30322, USA. Tel: 1-404-778-4857; Fax: 1-404-778-2578; e-mail: qcai@emory.edu
INTRODUCTION
Ursodeoxycholic acid (UDCA) constitutes around 3% of the
total bile acid pool in humans. Bacteria modify another
naturally occurring bile acid, chenodeoxycholic acid, in the
gut to form UDCA. The UDCA is a primary bile acid found in
bears, and it was discovered in polar bears by Swedish and
Danish explorers in Greenland in the early 1900s. Later UDCA
was isolated from the black bear and given its current name
for being an isomer of deoxycholic acid.
1
The mechanism of action for UDCA is multifactorial. First,
UDCA is hydrophilic whereas many other bile acids are
hydrophobic and therefore more cytotoxic to hepatocytes. The
UDCA competes with dominant endogenous bile acids for
absorption in the terminal ileum, making the bile acid pool
more hydrophilic.
2,3
Second, UDCA has a direct protective
effect on hepatocytes against bile acid-induced apoptosis.
3
Third, in cholestatic diseases, the retention of toxic bile acids
leads to cell injury. The UDCA counters this effect by
stimulating hepatocytes and bile duct epithelial cells to
secrete bile (Figure 1).
4
The UDCA is generally a well-
tolerated drug, but weight gain is a well-documented side
effect. Patients gain on average 2.2 kg in the first year of
treatment and their weight stabilizes thereafter.
5
PRIMARY BILIARY CIRRHOSIS
In primary biliary cirrhosis (PBC), an immune reaction
targets bile duct epithelium and destroys intrahepatic ducts.
Subsequent cholestasis leads to damage to hepatocytes and
can eventually result in cirrhosis in up to 25% of patients.
2
The UDCA at 1315 mg/kg/day is approved for treatment of
PBC by the United States Food and Drug Administration, and
UDCA is the only disease-modifying agent recommended by
the American Association for the Study of Liver Disease
(AASLD) for PBC.
6
Several trials show that UDCA improves
transplant-free survival, delays histologic progression of liver
disease, and improves biochemical markers of the disease.
6,7
Patients in early histologic stage of PBC (I or II) on liver
biopsy who are treated with UDCA have the best outcomes
and have been shown to have survival rates similar to control
populations without PBC.
8,9
In treated patients, survival rates
are better than rates predicted by the Mayo model.
810
When treating a PBC patient with UDCA, improvement in
transaminases and bilirubin levels is a favorable prognostic
factor. Transplant-free survival is best predicted biochemi-
cally by lower levels of alkaline phosphatase, aspartate
aminotransferase (AST), and bilirubin. Patients with lower
biochemical markers had a 10-year transplant-free survival
rate of 90% compared to 51% in patients with higher levels in
one study.
11
Despite an increase in the total number of liver
transplants over a 12-year period ending in 2006, the number
of transplants for PBC patients declined over the same time
period. This finding suggests that UDCA has been successful
as the primary treatment for PBC.
12
Ursodeoxycholic acid may also decrease the risk of devel-
oping esophageal varices in PBC patients. A prospective trial
following 180 patients with PBC for 4 years showed that 16%
of patients treated with UDCA developed esophageal varices
versus 58% of those given placebo.
13
This effect may be due
to delayed progression of advancing liver disease, as opposed
to a protective effect against portal hypertension.
ANNALS OF GASTROENTEROLOGY & HEPATOLOGY REVIEW ARTICLE
www.slm-gastroenterology.com 1 AGH 2011; 000:(000). Month 2011
San Lucas Medical, LLC
Several meta-analyses have shown conflicting results
regarding outcomes in PBC patients treated with UDCA.
Two meta-analyses showed no benefit on mortality or liver
transplant rates.
14,15
Common criticisms of these analyses are
that they included studies with inadequate follow-up times
and small doses of UDCA.
2,6
Two other meta-analyses
demonstrated an improvement in survival with no liver
transplant.
16,17
A 2006 meta-analysis requiring at least a
mid-dose of UDCA (10 mg/kg/day or more) and long-term
follow-up of at least 2 years showed an odds ratio of 0.65 for
liver transplant and 0.75 for death or liver transplant in
patients receiving UDCA versus placebo or no treatment.
16
Current AASLD guidelines recommend a dose of 1315 mg/
kg/day for PBC in patients with abnormal liver markers with a
cholestatic pattern, regardless of histological stage. Patients
with PBC but no elevation of liver markers are not advised to
use UDCA.
6
Patients discontinuing UDCA tend to have liver
biochemical markers return to pretreatment values, therefore
treatment is continued indefinitely.
2
Patients awaiting trans-
plant may be treated with UDCA as well.
18
The recommended dose of 1315 mg/kg/day is based on a
study comparing low dose (57 mg/kg/day), standard dose
(1315 mg/kg/day), and high dose (2325 mg/kg/day) UDCA.
Maximum improvement in alkaline phosphatase, AST, the
amount of UDCA in bile, and Mayo risk score were seen with
the standard dose. There were no additional side effects with
this dose. The high dose did not have additional side effects
but also was not shown to be of any additional benefit.
19
The use of UDCA in combination with other medications
has been considered. A recent study suggests that patients
with suboptimal biochemical response to UDCA after 1 year
may derive benefit from a combination of UDCA, budesonide
(6 mg/day) and mycophenolate mofetil (1.5 g/day).
20
Finally,
there is also evidence that UDCA is effective when combined
with corticosteroids in lowering serum biochemistries
in patients with PBC and autoimmune hepatitis overlap
syndrome.
21
PRIMARY SCLEROSING CHOLANGITIS
Initial studies of UDCA in primary sclerosing cholangitis
(PSC) showed improvement in biochemical markers, histo-
logical features, and clinical symptoms of pruritis and
fatigue.
2225
However, in 1997 there was a larger randomized,
double-blind trial comparing UDCA with placebo in treating
PSC. The dose was 1315 mg/kg/day with a median follow-up
of 2.2 years. There was no difference between the treatment
and the placebo groups when examining the combined
outcome of death, need for transplant, histological progres-
sion, development of varices, ascites, encephalopathy, fati-
gue, or pruritis.
26
Later smaller studies suggested that higher doses may be
of more benefit. In three studies, doses ranging from 17 to
30 mg/kg/day improved serum biochemistries, cholangio-
graphic appearance, rate of liver fibrosis, or Mayo risk
score.
2729
Finally, a trial compared 10, 20, and 30 mg/kg/
day doses and the Mayo risk score was significantly better in
the high dose group.
30
Despite these successes with high dose UDCA, a rando-
mized, double-blind placebo-controlled trial of high dose
UDCA by Lindor et al looking at 150 patients with PSC
showed poorer outcomes among patients treated with
UDCA. Patients were given 2830 mg/kg/day of UDCA.
The study included long-term follow-up and measured the
following primary outcomes: development of cirrhosis,
varices, cholangiocarcinoma, liver transplantation, and
death. Thirty nine percent of patients in the UDCA group
reached one of the above endpoints by the end of the study
versus 26% in the placebo group. The UDCA group had
lower serum liver tests.
31
The authors offered several
explanations for the results. Higher doses may have allowed
more drugs to reach the colon with subsequent conversion
into hepatotoxic bile acids. High dose UDCA may also
inhibit the apoptosis of activated stellate cells, allowing for
more fibrinogenesis and liver disease. Finally, UDCA may
exacerbate hepatocyte necrosis in the setting of biliary
obstruction and PSC.
31
The AASLD gives a 1A recommendation (strong recom-
mendation with high quality evidence) against the use of
UDCA in patients with PSC.
32
As an editorial on the negative
study above points out, the role of UDCA for PSC remains
unclear. Low or medium dose UDCA for PSC could be
further evaluated in large trials with longer durations of
treatment.
33
Figure 1. Mechanisms of action of UDCA. Ursodeoxycholic acid decreases
the cytotoxicity of bile by making the bile acid pool more hydrophilic. The
UDCA also directly inhibits apoptosis induced by hydrophobic bile acids.
Finally, UDCA stimulates secretion of bile, decreasing the retention of toxic
bile acids. Reprinted by permission from MacMillan Publishers Ltd: Beuers
U. Drug insight: mechanisms and sites of action of ursodeoxycholic acid in
cholestasis.
Nat Clin Pract Gastroenterol Hepatol.
2006;3(6):318328.
Annals of Gastroenterology & Hepatology
AGH 2011; 000:(000). Month 2011 2 www.slm-gastroenterology.com
San Lucas Medical, LLC
CHOLELITHIASIS
Cholecystectomy is the treatment of choice for patients with
symptomatic cholelithiasis. However, in certain cases of
uncomplicated cholelithiasis, UDCA may be useful. A rando-
mized, double-blind placebo-controlled trial of 177 patients
with highly symptomatic gallstones awaiting cholecystectomy
showed that the rate of biliary colic, nonsevere biliary pain,
and analgesic intake were similar between the UDCA and
placebo groups over a 90-day follow-up period. This indicates
that UDCA does not have a role in alleviating biliary pain in
the short-term among patients awaiting cholecystectomy.
34
The UDCA may however be useful in longer-term treatment
of gallstones in patients not undergoing cholecystectomy. In
a nonrandomized cohort of 527 patients with uncomplicated
gallstones, UDCA was associated with decreased need for
cholecystectomy and decreased biliary pain. This was inde-
pendent of the analysis of gallstone dissolution.
35
Among patients with an intact gallbladder, recurrent acute
pancreatitis may occur less frequently when UDCA is used,
especially if microlithiasis may be playing a role.
36
In patients
with recurrent pancreatitis who will not undergo cholecys-
tectomy, performing a sphincterotomy is advised as well.
37
In certain populations, UDCA may effectively dissolve
cholesterol gallstones by solubilizing cholesterol in bile.
A meta-analysis showed that UDCA successfully dissolved
radiolucent stones in 37% of patients. The efficacy increased
with decreasing size of the stones.
38
Other analyses have
shown dissolution rates of 30%50%.
39
However, stones
frequently return after dissolution with UDCA. Single stones
have the lowest rate of recurrence.
40,41
Recurrence rates have
been shown to be 12.5% in the first year and 61% by 11 years
in one study.
41
Patient selection is very important for successful dissolution
of gallstones with UDCA. Ideal candidates for UDCA therapy
should have a functioning gallbladder, their largest stone
should be ideally less than 5 mm and certainly less than 10
mm, and the stones should be of the cholesterol variety and
thus radiolucent.
35,42,43
Ursodeoxycholic acid has been shown to reduce the
incidence of rapid weight loss induced gallstone formation
in patients undergoing gastric bypass. A randomized placebo-
controlled study using 600 mg daily for 6 months reduced the
incidence of gallstone formation over 6 years following
gastric bypass from 32% with placebo to 2% with UDCA.
44
MICROLITHIASIS
Treatment of microlithiasis may include cholecystectomy,
endoscopic sphincterotomy, or UDCA. The UDCA can
prevent recurrence of acute ‘‘idiopathic’’ pancreatitis, which
is often caused by biliary sludge and microlithiasis in patients
with an intact gallbladder.
36,45
In a study of patients with
recurrent pancreatitis and cholesterol monohydrate crystals in
their bile, UDCA eliminated biliary microlithiasis and pre-
vented recurrence of pancreatitis over a 44-month period.
36
In
another small study, 4 out of 5 patients with biliary sludge
and microlithiasis treated with UDCA achieved long-term
relief from recurrent pancreatitis.
45,46
Because of the risk of
recurrence, however, cholecystectomy is routinely recom-
mended in patients with biliary sludge who have had acute
pancreatitis.
Many patients who undergo cholecystectomy for sympto-
matic gallstones continue to experience pain. Approximately
one-third of all patients undergoing cholecystectomy will
experience this postcholecystectomy syndrome. The patho-
physiology of postcholecystectomy syndrome has not been
clearly delineated, though several mechanisms have been
proposed including sphincter of Oddi dysfunction.
47
Microlithiasis has been identified in some patients who
have undergone cholecystectomy, and one study demon-
strates that it may be a cause of postcholecystectomy pain.
The UDCA may be useful for treatment in these cases. The
study looked at 118 patients with postcholecystectomy
syndrome, and 12 (10%) were found to have microlithiasis
on examination of their bile. These 12 patients were further
studied. In the first phase of the study, 6 patients received
UDCA and had a significant reduction in pain compared
to the untreated 6 patients. In the second phase, the other
6 patients were treated with UDCA and also experienced a
significant reduction in pain. The UDCA may be of benefit in
patients with postcholecystectomy pain and microlithiasis.
47
This study was limited by several factors including the small
sample size of 12 and the lack of placebo control. Bile
analysis was not performed after treatment to confirm the
resolution of microlithiasis as the reason for pain relief. Also,
the appropriate duration of treatment is not known. It is not
known whether endoscopic sphincterotomy is an effective
therapy in patients with microlithiasis and postcholecystect-
omy syndrome.
47
MISCELLANEOUS CHOLESTATIC DISEASES
Intrahepatic cholestasis of pregnancy (ICP) manifests as
pruritis with elevated serum bile acids in the second half
of pregnancy. It generally resolves after pregnancy with only
rare complications for the mother. Fetal complications are
more common and are associated with elevated maternal
serum bile acid concentrations. The mechanism of disease
involves improper biliary transport across the canalicular
membrane.
48
Recent trials have evaluated the utility of UDCA in treating
ICP. In one study, patients received either UDCA at a dose of
810 mg/kg of body weight daily or cholestyramine. The
UDCA group had a decrease in serum aminotransferases,
serum bile acid levels, and pruritis. Babies in the UDCA group
were delivered significantly closer to term without adverse
events from UDCA.
49
In another trial comparing UDCA at
1 gm daily to dexamethasone, patients receiving UDCA
showed a decrease in serum alanine transaminase (ALT)
and bilirubin. In the women with the highest initial serum
bile acid levels, UDCA also decreased pruritis and serum bile
acid levels. There was no significant effect on fetal complica-
tions.
50
There have been no reports of fetal complications
Role of Ursodeoxycholic Acid in Digestive Diseases
www.slm-gastroenterology.com 3 AGH 2011; 000:(000). Month 2011
San Lucas Medical, LLC
with maternal use of UDCA, but no study has been powered
to detect such events.
51
Patients on long-term total parenteral nutrition (TPN) are at
risk for hepatobiliary complications including cholesta-
sis.
52,53
A study of nine patients with cholestasis due to
TPN who were treated with UDCA at 10.612 mg/kg/day
showed a significant reduction in gamma-glutamyltransferase
(GGT) and ALT during treatment periods compared to
nontreatment periods. There was no significant difference
in bilirubin, AST, or alkaline phosphatase.
54
Three small
retrospective studies examining UDCA in pediatric popula-
tions receiving TPN showed improvements in liver biochem-
istries as well.
5557
There is no evidence regarding the use of UDCA in the
treatment of hepatotoxic drug reactions. However, given the
benefit of UDCA in other cholestatic diseases, it is a
reasonable assumption that UDCA may be of benefit in
cholestatic drug hepatotoxicity with minimal risk to the
patient. A dose of 1315 mg/kg/day has been suggested.
58
BONE MARROW TRANSPLANTATION
Various hepatic complications are associated with hemato-
poietic cell transplantation including veno-occlusive disease,
hepatic graft-versus-host disease (GVHD), and liver
failure.
59,60
A prospective randomized trial examining pre-
vention of hepatic complications after allogeneic stem cell
transplantation suggests a role for UDCA. Patients received
either UDCA or placebo from the day preceding conditioning
until day 90 after transplantation. The UDCA group had
significantly lower serum bilirubin and ALT levels, a sig-
nificantly lower incidence of grade III or IV acute GVHD, and
improved overall survival at 1 year (71 vs 55%). There was no
difference in the incidence of veno-occlusive disease.
61
A small study examined the use of UDCA for the treatment
of hepatic GVHD. Twelve allogeneic bone marrow transplant
patients received 6 to 12 weeks of UDCA for treatment of
refractory GVHD. Results showed improvement in AST,
bilirubin, and alkaline phosphatase with approximately a
one-third decline in each. However, there is no evidence for
long-term use.
62
VIRAL HEPATITIS
Ursodeoxycholic acid has been associated with improved
serum transaminases in patients with chronic hepatitis C
despite having no influence on the viral load. The mechanism
likely involves the cytoprotective effect of UDCA.
63
A trial in
1994 demonstrated that UDCA at a dose of 600 or 900 mg/day
for 16 weeks was associated with a 26% reduction in ALT and
a 50% reduction in GGT.
64
A recent large, double-blind trial
evaluated serum biochemical response to UDCA at either 150,
600, or 900 mg/day for 24 weeks in 596 patients with chronic
hepatitis C. This trial confirmed that 600 mg/day was the
preferred dose for maximal response in transaminases, but
serum GGT decreased significantly more in the 900 mg/day
group. This may be a reflection of the choleretic effect of
UDCA. There was no difference in adverse events among the
groups.
65
Progression of fibrosis in chronic hepatitis C has been
linked to serum transaminase levels.
66
However, trials of
UDCA have failed to show benefit in histological progression.
This may be due to the relatively short duration of follow-up
of the studies to date, which have been 6 to 12 months.
63,67,68
A recent Cochrane review of UDCA in viral hepatitis showed
an improvement in liver biochemistries for Hepatitis B and C.
The UDCA did not affect clearance of virus, and there was no
evidence to indicate improvement in outcomes such as
progression to cirrhosis or incidence of hepatocellular
carcinoma.
69
NONALCOHOLIC FATTY LIVER DISEASE
Nonalcoholic fatty liver disease (NAFLD) includes hepatic
steatosis and nonalcoholic steatohepatitis (NASH), which can
progress to cirrhosis and hepatocellular carcinoma.
70
A pilot
study suggested a role for UDCA in treating NASH.
71
However, a randomized controlled trial of 166 patients who
received either 1315 mg/kg/day of UDCA or placebo for 2
years showed no significant difference in serum liver
biochemistries or histology.
72
The authors of this study
suggest that perhaps the dose of UDCA used was not high
enough to detect a benefit. Another study using a fixed dose
of 1200 mg/day of UDCA versus placebo also failed to show a
benefit for serum transaminases.
73
Finally, a Cochrane review
with meta-analysis examined four randomized trials of UDCA
for NAFLD and was unable to detect a significant benefit for
mortality or biochemistries with UDCA.
70
CHEMOPROPHYLAXIS OF COLORECTAL
CANCER
The use of UDCA in patients with ulcerative colitis (UC) and
PSC for chemoprevention of colorectal cancer has also been
investigated. A cross-sectional study of 59 patients with UC
and PSC revealed an odds ratio of 0.18 for the development of
colonic dysplasia in patients taking UDCA versus patients not
taking UDCA.
74
In another study, 52 patients with UC and
PSC received either UDCA for a median of 42 months or
placebo for a median of 40 months. The relative risk of
developing dysplasia or cancer was 0.26 for the UDCA group
compared to the placebo group.
75
Finally, a retrospective analysis compared 28 patients with
UC and PSC who were treated with UDCA for at least 6
months to 92 patients who did not receive UDCA. There was
no significant difference in the incidence of dysplasia or
cancer.
76
Given the potential adverse outcomes in PSC
patients taking UDCA and the inconclusive evidence, the
AASLD recommends against the use of UDCA for chemo-
prophylaxis.
32
CYSTIC FIBROSIS
In cystic fibrosis patients with evidence of hepatic involve-
ment, UDCA was shown in an observational study to be
Annals of Gastroenterology & Hepatology
AGH 2011; 000:(000). Month 2011 4 www.slm-gastroenterology.com
San Lucas Medical, LLC
associated with a delay in the progression of liver disease. No
solid evidence for its use in cystic fibrosis is available in the
form of randomized controlled trials.
77
CONCLUSION
Ursodeoxycholic acid is a well-tolerated and safe drug with
a wide range of potential clinical uses (Table 1). In PBC, the
evidence favors the use of UDCA as a disease-modifying agent
that improves transplant-free survival. The UDCA is useful for
dissolving gallstones and preventing symptoms in carefully
selected patients with cholelithiasis; namely, in patients with
small gallstones and a functioning gallbladder who are not
undergoing cholecystectomy. The UDCA is effective in
preventing cholelithiasis in patients who have undergone
gastric bypass surgery.
In PSC, the evidence is equivocal but suggests potential
harm from high-dose UDCA use. Finally, there is promise for
the potential use of UDCA in microlithiasis, cholestatic
diseases such as ICP and liver injury from TPN, as well as
in chronic viral hepatitis, bone marrow transplantation,
chemoprophylaxis in UC and PSC, and cystic fibrosis. More
research is warranted in these areas.
Disclosure: The authors declare no conflict of interest.
REFERENCES
1. Hagey LR, Crombie DL, Espinosa E, et al. Ursodeoxycholic acid in the
ursidae: biliary bile acids of bears, pandas, and related carnivores. J Lipid
Res. 1993;34(11):19111917.
2. Lindor K. Ursodeoxycholic acid for the treatment of primary biliary
cirrhosis. N Engl J Med. 2007;357:15241529.
3. Paumgartner G, Beuers U. Ursodeoxycholic acid in cholestatic liver
disease: mechanisms of action and therapeutic use revisited [review].
Hepatology. 2002;36(3):525531.
4. Perez MJ, Briz O. Bile-acid-induced cell injury and protection [review].
World J Gastroenterol. 2009;15(14):16771689.
5. Siegel JL, Jorgensen R, Angulo P, et al. Treatment with ursodeoxycholic
acid is associated with weight gain in patients with primary biliary
cirrhosis. J Clin Gastroenterol. 2003;37(2):183185.
6. Lindor KD, Gershwin ME, Poupon R, et al. Primary biliary cirrhosis.
Hepatology. 2009;50:219308.
7. Poupon R. Primary biliary cirrhosis: a 2010 update. Journal of Hepatology.
2010;52:745758.
8. Corpechot C, Carrat F, Bahr A, et al. The effect of ursodeoxycholic acid
therapy on the natural course of primary biliary cirrhosis. Gastroenterology.
2005;128:297203.
9. Kuiper EM, Hansen BE, de Vries RA, et al. Dutch PBC Study Group.
Improved prognosis of patients with primary biliary cirrhosis that have a
biochemical response to ursodeoxycholic acid [published online ahead of
print January 14, 2009]. Gastroenterology. 2009;136(4):12811287.
10. Pare
´
s A, Caballerı
´
a L, Rode
´
s J. Excellent long-term survival in patients
with primary biliary cirrhosis and biochemical response to ursodeoxy-
cholic acid. Gastroenterology. 2006;130(3):715720.
11. Corpechot C, Abenavoli L, Rabahi N, et al. Biochemical response to
ursodeoxycholic acid and long-term prognosis in primary biliary
cirrhosis. Hepatology. 2008;48(3):871877.
12. Lee J, Belanger A, Doucette JT, et al. Transplantation trends in primary
biliary cirrhosis [published online ahead of print September 27, 2007].
Clin Gastroenterol Hepatol. 2007;5(11):13131315.
13. Lindor KD, Jorgensen RA, Therneau TM, et al. Ursodeoxycholic acid
delays the onset of esophageal varices in primary biliary cirrhosis. Mayo
Clin Proc. 1997;72(12):11371140.
14. Gong Y, Huang ZB, Christensen E, et al. Ursodeoxycholic acid for primary
biliary cirrhosis. Cochrane Database of Systematic Reviews. 2008;3:CD000551.
15. Goulis J, Leandro G, Burroughs AK. Randomised controlled trials of
ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-
analysis. Lancet. 1999;354:10531060.
16. Shi J, Wu C, Lin Y, et al. Long-term effects of mid-dose ursodeoxycholic
acid in primary biliary cirrhosis: a meta-analysis of randomized
controlled trials. Am J Gastroenterol. 2006;101:15291538.
17. Poupon RE, Lindor KD, Cauch-Dudek K, et al. Combined analysis of
randomized controlled trials of ursodeoxycholic acid in primary biliary
cirrhosis. Gastroenterology. 1997;113:884890.
18. Heathcote EJ, Stone J, Cauch-Dudek K, et al. Effect of pretransplantation
ursodeoxycholic acid therapy on the outcome of liver transplantation
in patients with primary biliary cirrhosis. Liver Transpl Surg. 1999;5(4):
269274.
19. Angulo P, Dickson ER, Therneau TM, et al. Comparison of three doses of
ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a
randomized trial. J Hepatol. 1999;30(5):830835.
20. Rabahi N, Chre
´
tien Y, Gaouar F, et al. Triple therapy with ursodeoxy-
cholic acid, budesonide and mycophenolate mofetil in patients with
features of severe PBC not responding to ursodeoxycholic acid alone.
Gastroenterol Clin Biol. 2010;34:283287.
21. Chazouille
`
res O, Wendum D, Serfaty L, et al. Primary biliary cirrhosis-
autoimmune hepatitis overlap syndrome: clinical features and response
to therapy. Hepatology. 1998;28(2):296301.
22. Beuers U, Spengler U, Kruis W, et al. Ursodeoxycholic acid for treatment
of primary sclerosing cholangitis: a placebo-controlled trial. Hepatology.
1992;16(3):707714.
23. Stiehl A, Walker S, Stiehl L, et al. Effect of ursodeoxycholic acid on liver
and bile duct disease in primary sclerosing cholangitis. A 3-year pilot
study with a placebo-controlled study period. J Hepatol. 1994;20(1):5764.
24. Chazouille
`
res O, Poupon R, Capron JP, et al. Ursodeoxycholic acid for
primary sclerosing cholangitis. J Hepatol. 1990;11(1):120123.
25. O’Brien CB, Senior JR, Arora-Mirchandani R, et al. Ursodeoxycholic acid
for the treatment of primary sclerosing cholangitis: a 30-month pilot
study. Hepatology. 1991;14(5):838847.
26. Lindor KD. Ursodiol for primary sclerosing cholangitis. Mayo Primary
Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. N Engl J Med.
1997;336(10):691695.
27. Mitchell SA, Bansi DS, Hunt N, et al. A preliminary trial of high-dose
ursodeoxycholic acid in primary sclerosing cholangitis. Gastroenterology.
2001;121(4):900907.
Table 1. Potential Uses of UDCA
Conditions with evidence supporting use
Primary biliary cirrhosis
Cholelithiasis
Conditions with some evidence supporting use requiring further investigation
Microlithiasis and pancreatitis
Microlithiasis and postcholecystectomy syndrome
Intrahepatic cholestasis of pregnancy
TPN-induced liver injury
Bone marrow transplantation and GVHD
Viral hepatitis
Nonalcoholic fatty liver disease
Chemoprophylaxis of colorectal cancer for UC and PSC
Cystic fibrosis
Conditions with evidence against use
Primary sclerosing cholangitis
Conditions with theoretical benefit but no evidence
Drug-induced hepatotoxicity
Role of Ursodeoxycholic Acid in Digestive Diseases
www.slm-gastroenterology.com 5 AGH 2011; 000:(000). Month 2011
San Lucas Medical, LLC
28. Harnois DM, Angulo P, Jorgensen RA, et al. High-dose ursodeoxycholic
acid as a therapy for patients with primary sclerosing cholangitis. Am J
Gastroenterol. 2001;96(5):15581562.
29. Olsson R, Boberg KM, de Muckadell OS, et al. High-dose ursodeoxy-
cholic acid in primary sclerosing cholangitis: a 5-year multicenter,
randomized, controlled study. Gastroenterology. 2005;129(5):14641472.
30. Cullen SN, Rust C, Fleming K, et al. High dose ursodeoxycholic acid for
the treatment of primary sclerosing cholangitis is safe and effective
[published online ahead of print February 14, 2008]. J Hepatol.
2008;48(5):792800.
31. Lindor KD, Kowdley KV, Luketic VA, et al. High-dose ursodeoxycholic
acid for the treatment of primary sclerosing cholangitis. Hepatology.
2009;50(3):808814.
32. Chapman R, Fevery J, Kalloo A, et al. Diagnosis and management of
primary sclerosing cholangitis. American Association for the Study of
Liver Diseases. Hepatology. 2010;51(2):660678.
33. Chapman RW. High-dose ursodeoxycholic acid in the treatment of
primary sclerosing cholangitis: throwing the urso out with the bath-
water? Hepatology. 2009;50(3):671673.
34. Venneman NG, Besselink MG, Keulemans YC, et al. Ursodeoxycholic acid
exerts no beneficial effect in patients with symptomatic gallstones
awaiting cholecystectomy. Hepatology. 2006;43(6):12761283.
35. Tomida S, Abei M, Yamaguchi T, et al. Long-term ursodeoxycholic acid
therapy is associated with reduced risk of biliary pain and acute
cholecystitis in patients with gallbladder stones: a cohort analysis.
Hepatology. 1999;30:613.
36. Ros E, Navarro S, Bru C, et al. Occult microlithiasis in idiopathic acute
pancreatitis: prevention of relapses by cholecystectomy or ursodeoxy-
cholic acid therapy. Gastroenterology. 1991;101(6):17011709.
37. Van Geenen E, van der Peet D, Mulder C, et al. Recurrent acute biliary
pancreatitis: the protective role of cholecystectomy and endoscopic
sphincterotomy. Surg Endosc. 2009;23:950956.
38. May GR, Sutherland LR, Shaffer EA. Efficacy of bile acid therapy for
gallstone dissolution: a meta-analysis of randomized trials. Aliment
Pharmacol Ther. 1993;7(2):139148.
39. Rubin RA, Kowalski TE, Khandelwal M, et al. Ursodiol for hepatobiliary
disorders. Ann Intern Med. 1994;121(3):207218.
40. Petroni ML, Jazrawi RP, Pazzi P, et al. Risk factors for the development of
gallstone recurrence following medical dissolution. The British-Italian
Gallstone Study Group. Eur J Gastroenterol Hepatol. 2000;12(6):695700.
41. Villanova N, Bazzoli F, Taroni F, et al. Gallstone recurrence after
successful oral bile acid treatment. A 12-year follow-up study and
evaluation of long-term postdissolution treatment. Gastroenterology.
1989;97(3):726731.
42. Fromm H, Malavolti M. Bile acid dissolution therapy of gallbladder
stones. Baillieres Clin Gastroenterol. 1992;6(4):689695.
43. Caroli A, Del Favero G, Di Mario F, et al. Computed tomography in
predicting gall stone solubility: a prospective trial. Gut. 1992;33(5):698
700.
44. Sugerman HJ, Brewer WH, Shiffman ML, et al. A multicenter, placebo-
controlled, randomized, double-blind, prospective trial of prophylactic
ursodiol for the prevention of gallstone formation following gastric-
bypass-induced rapid weight loss. Am J Surg. 1995;169(1):9196; discus-
sion 9697.
45. Saraswat VA, Sharma BC, Agarwal DK, et al. Biliary microlithiasis in
patients with idiopathic acute pancreatitis and unexplained biliary pain:
response to therapy. J Gastroenterol Hepatol. 2004;19(10):12061211.
46. Testoni PA, Caporuscio S, Bagnolo F, et al. Idiopathic recurrent
pancreatitis: long-term results after ERCP, endoscopic sphincterotomy,
or ursodeoxycholic acid treatment. Am J Gastroenterol. 2000;95(7):1702
1707.
47. Okoro N, Patel A, Goldstein M, et al. Ursodeoxycholic acid treatment for
patients with postcholecystectomy pain and bile microlithiasis. Gastro-
intest Endosc. 2008;68(1):6974.
48. Joshi D, James A, Quaglia A, et al. Liver disease in pregnancy. Lancet.
2010;375(9714):594605.
49. Kondrackiene J, Beuers U, Kupcinskas L. Efficacy and safety of
ursodeoxycholic acid versus cholestyramine in intrahepatic cholestasis
of pregnancy. Gastroenterology. 2005;129(3):894901.
50. Glantz A, Marschall HU, Lammert F, et al. Intrahepatic cholestasis of
pregnancy: a randomized controlled trial comparing dexamethasone and
ursodeoxycholic acid. Hepatology. 2005;42(6):13991405.
51. Geenes V, Williamson C. Intrahepatic cholestasis of pregnancy. World J
Gastroenterol. 2009;15(17):20492066.
52. Raman M, Allard JP. Parenteral nutrition related hepato-biliary disease in
adults [review]. Appl Physiol Nutr Metab. 2007;32(4):646654.
53. Cavicchi M, Beau P, Crenn P, et al. Prevalence of liver disease and
contributing factors in patients receiving home parenteral nutrition for
permanent intestinal failure. Ann Intern Med. 2000;132(7):525532.
54. Beau P, Labat-Labourdette J, Ingrand P, et al. Is ursodeoxycholic acid an
effective therapy for total parenteral nutrition-related liver disease?
J Hepatol. 1994;20(2):240244.
55. Levine A, Maayan A, Shamir R, et al. Parenteral nutrition-associated
cholestasis in preterm neonates: evaluation of ursodeoxycholic acid
treatment. J Pediatr Endocrinol Metab. 1999;12(4):549553.
56. Spagnuolo MI, Iorio R, Vegnente A, et al. Ursodeoxycholic acid for
treatment of cholestasis in children on long-term total parenteral
nutrition: a pilot study. Gastroenterology. 1996;111(3):716719.
57. Chen CY, Tsao PN, Chen HL, et al. Ursodeoxycholic acid (UDCA) therapy
in very-low-birth-weight infants with parenteral nutrition-associated
cholestasis. J Pediatr. 2004;145(3):317321.
58. Nathwani RA, Kaplowitz N. Drug hepatotoxicity [review]. Clin Liver Dis.
2006;10(2):207217, vii.
59. Essell JH, Schroeder MT, Harman GS, et al. Ursodiol prophylaxis against
hepatic complications of allogeneic bone marrow transplantation. A
randomized, double-blind, placebo-controlled trial. Ann Intern Med.
1998;128:975981.
60. Park SH, Lee MH, Lee H, et al. A randomized trial of heparin plus
ursodiol vs. heparin alone to prevent hepatic veno-occlusive disease after
hematopoietic stem cell transplantation. Bone Marrow Transplant.
2002;29(2):137143.
61. Ruutu T, Eriksson B, Remes K, et al. Nordic Bone Marrow Trans-
plantation Group. Ursodeoxycholic acid for the prevention of hepatic
complications in allogeneic stem cell transplantation. Blood.
2002;100(6):19771983.
62. Fried RH, Murakami CS, Fisher LD, et al. Ursodeoxycholic acid treatment
of refractory chronic graft-versus-host disease of the liver. Ann Intern Med.
1992;116(8):624629.
63. Poupon R, Serfaty L. Ursodeoxycholic acid in chronic hepatitis C
[review]. Gut. 2007;56(12):16521653.
64. Takano S, Ito Y, Yokosuka O, et al. A multicenter randomized controlled
dose study of ursodeoxycholic acid for chronic hepatitis C. Hepatology.
1994;20(3):558564.
65. Omata M, Yoshida H, Toyota J, et al; Japanese C-Viral Hepatitis
Network. A large-scale, multicentre, double-blind trial of ursodeoxy-
cholic acid in patients with chronic hepatitis C [published online ahead
of print June 15, 2007]. Gut. 2007;56(12):17471753.
66. Ghany MG, Kleiner DE, Alter H, et al. Progression of fibrosis in chronic
hepatitis C. Gastroenterology. 2003;124(1):97104.
67. Poupon RE, Bonnand AM, Queneau PE, et al. Randomized trial of
interferon-alpha plus ursodeoxycholic acid versus interferon plus placebo
in patients with chronic hepatitis C resistant to interferon. Scand J
Gastroenterol. 2000;35(6):642649.
68. Attili AF, Rusticali A, Varriale M, et al. The effect of ursodeoxycholic acid
on serum enzymes and liver histology in patients with chronic active
hepatitis. A 12-month double-blind, placebo-controlled trial. J Hepatol.
1994;20(3):315320.
69. Chen W, Liu J, Gluud C. Bile acids for viral hepatitis [review]. Cochrane
Database Syst Rev. 2007;(4):CD003181.
70. Orlando R, Azzalini L, Orando S, et al. Bile acids for non-alcoholic fatty
liver disease and/or steatohepatitis [review]. Cochrane Database Syst Rev.
2007;(1):CD005160.
71. Laurin J, Lindor KD, Crippin JS, et al. Ursodeoxycholic acid or clofibrate
in the treatment of non-alcohol-induced steatohepatitis: a pilot study.
Hepatology. 1996;23(6):14641467.
72. Lindor KD, Kowdley KV, Heathcote EJ, et al. Ursodeoxycholic acid for
treatment of nonalcoholic steatohepatitis: results of a randomized trial.
Hepatology. 2004;39(3):770778.
Annals of Gastroenterology & Hepatology
AGH 2011; 000:(000). Month 2011 6 www.slm-gastroenterology.com
San Lucas Medical, LLC
73. Me
´
ndez-Sa
´
nchez N, Gonza
´
lez V, Cha
´
vez-Tapia N, et al. Weight reduction
and ursodeoxycholic acid in subjects with nonalcoholic fatty liver disease.
A double-blind, placebo-controlled trial. Hepatol. 2004;3(3):108112.
74. Tung BY, Emond MJ, Haggitt RC, et al. Ursodiol use is associated with
lower prevalence of colonic neoplasia in patients with ulcerative colitis
and primary sclerosing cholangitis. Ann Intern Med. 2001;134(2):8995.
75. Pardi DS, Loftus EV Jr, Kremers WK, et al. Ursodeoxycholic acid as a
chemopreventive agent in patients with ulcerative colitis and primary
sclerosing cholangitis. Gastroenterology. 2003;124:889893.
76. Wolf JM, Rybicki LA, Lashner BA. The impact of ursodeoxycholic acid on
cancer, dysplasia and mortality in ulcerative colitis patients with primary
sclerosing cholangitis. Aliment Pharmacol Ther. 2005;22:783788.
77. Nousia-Arvanitakis S, Fotoulaki M, Economou H, et al. Long-term
prospective study of the effect of ursodeoxycholic acid on cystic
fibrosis-related liver disease. J Clin Gastroenterol. 2001;32(4):324328.
Role of Ursodeoxycholic Acid in Digestive Diseases
www.slm-gastroenterology.com 7 AGH 2011; 000:(000). Month 2011
... The predominant bile acids in humans are chenodeoxycholic acid (CDCA; 30%-50%) and cholic acid (CA; 27%-48%) with only about 0.4%-5% being ursodeoxycholic acid (UDCA) (Rossi, Converse, & Hofmann, 1987). Bears are unique in being able to produce TUDCA from bacterial modification of TCDCA in the gut (Gamboa, Tian, Massaad, Reshamwala, & Cai, 2011 The bile acids in the gallbladder of bears are tauroursodeoxycholate (30%-39%), taurochenodeoxycholate (16%-30%), and taurocholate (3%-34%). These can be further metabolized into lithocholate under certain physiological conditions. ...
... (CDCA; 30%-50%) and cholic acid (CA; 27%-48%) with only about 0.4%-5% being ursodeoxycholic acid (UDCA) (Rossi et al., 1987). TUDCA is produced from bacterial modification of TCDCA in the gut of bears (Gamboa et al., 2011) and the bile acid profile of black bears is unique in that it contains about 10 times more TUDCA to that of humans, and about 30%-40% to that of cattle, chicken, pig, and rabbit (Hagey et al., 1993;Wang, Feng, et al., 2011;Watanabe et al., 2009;Watanabe & Tsuneyama, 2012) (Table 2). Another bioactive constituent of bear bile, TCDCA, is found in appreciable concentrations in cattle (10%), chicken (7%), and pig (17%), with TCA also present in the cattle gallbladder (15%-20%) ( Table 2). ...
Article
Practitioners of traditional Chinese medicine (TCM) commonly prescribe medicinal formulations relying on the purported synergism of a combination of plant species, sometimes incorporating animal parts and minerals. Bear bile, obtained from either wild or farmed bears, is a commonly used constituent of traditional medicine formulations. With several bear species now listed under Convention on International Trade in Endangered Species of Wild Fauna and Flora as threatened with extinction and with bear farming being actively campaigned against on ethical grounds, it is important to seek and promote alternatives to the use of bear bile as medicine. This chapter describes and evaluates the scientific data relating to the efficacy of bear bile and potential alternatives to its use, including the use of bile from other animal species, the use of synthetic chemical alternatives, and the use of herbal substitutes.
... Прийом УДХК зумовлює підвищення бактерицидності жовчі й кишкового вмісту, зменшення бродильної й гнильної диспепсії, забезпечує метаболічний ефект, сприяючи зниженню сироваткового рівня глюкози, інсуліну й індексу НОМА, регулює метаболізм ліпідів, гомеостаз жовчних кислот, а також проліферацію й диференціацію холангіоцитів [22][23][24][25][26][27][28][29]. ...
Article
Full-text available
Primary biliary cirrhosis (PBC) is a chronic inflammatory autoimmune disease that mainly targets the cholangiocytes of the interlobular bile ducts in the liver. The condition primarily affects middle-aged women. Without treatment, PBC generally progresses to cirrhosis and eventually liver failure over a period of 10-20 years. PBC is a rare disease with prevalence of less than 1/2000. PBC is thought to result from a combination of multiple genetic factors and superimposed environmental triggers. The contribution of the genetic predisposition is evidenced by the familial clustering. Several risk factors, including exposure to infectious agents and chemical xenobiotics, have been suggested. Ursodeoxycholic acid (UDCA) is currently the only FDA-approved medical treatment for PBC. When administered at doses of 13-15 mg/kg/day, a majority of patients with PBC have a normal life expectancy without additional therapeutic measures. One out of three patients does not adequately respond to UDCA therapy and may need additional medical therapy and/or liver transplantation. This review summarises current knowledge on the epidemiology, ethiopathogenesis, clinical, and therapeutic aspects of PBC.
Article
Non-alcohol-induced steatohepatitis (NASH) is characterized by elevated serum aminotransferase activities with hepatic steatosis, inflammation, and occasionally fibrosis that may progress to cirrhosis. No established treatment exists for this potentially serious disorder. Our aim was to conduct a pilot study to evaluate the safety and estimate the efficacy of ursodeoxycholic acid (UDCA) and clofibrate in the treatment of NASH. Forty patients were diagnosed with NASH based on a compatible liver biopsy with other causes of liver disease, including alcohol abuse, excluded by history, serum tests, and use of ultrasound. Twenty-four patients received 13 to 15 mg/kg/d of UDCA for 12 months. Sixteen patients with hypertriglyceridemia were placed on clofibrate, 2 g/day for 12 months. Twenty-five women and 15 men entered the study. Six of 40 patients (15%) withdrew because of side effects. Four additional patients were withdrawn because of noncompliance; one of them later required liver transplantation. In the UDCA group, the decreases in mean serum levels of alkaline phosphatase, alanine transaminase (ALT), and gamma-glutamyl transpeptidase (GGT) as well as histological grade of steatosis were significant. Among the patients treated with clofibrate, no change from baseline was found in mean ALT, aspartate transaminase (AST), GGT, bilirubin, triglycerides, and cholesterol, or in histological grade of steatosis, inflammation, or fibrosis after 12 months of treatment as compared with entry. Alkaline phosphatase activities decreased significantly from baseline. Despite the known lipid-lowering effects of clofibrate, it did not appear to be of clinical benefit in the treatment of NASH in this 1-year pilot study. However, treatment of NASH with UDCA for 12 months resulted in significant improvement in alkaline phosphatase, ALT, GGT, and hepatic steatosis. The possible benefit of UDCA therapy should be further investigated in the context of a randomized, controlled trial. (Hepatology 1996 Jun;23(6):1464-7)
Article
The association of primary biliary cirrhosis (PBC) and autoimmune hepatitis (AIH) is thought to be rare, and its optimal treatment is unknown. Of 130 consecutive patients with a diagnosis of PBC, we identified 12 cases (9.2%) of overlap syndrome (10 females, 2 males; median age, 50 years) strictly defined by the presence of at least two of the three recognized biochemical, serological, and histological criteria of each disease. One patient had initially pure PBC and developed AIH characterized by a flare of alanine transaminase (ALT) (1,330 IU/L; N < 35), elevated immunoglobulin G (IgG) (42 g/L; N < 14.0), and presence of anti-smooth muscle antibodies (ASMA) after 20 months of ursodeoxycholic acid (UDCA) therapy. A complete clinical and biochemical remission was achieved under combination of corticosteroids and UDCA. Eleven patients had features of both diseases at presentation: high serum levels of alkaline phosphatase (AP) (median: 280 IU/L; N < 100), ALT (140 IU/L), and IgG (30.8 g/L), presence of mitochondrial antibodies (n = 9) or ASMA (n = 9), florid bile duct lesions (n = 8), and moderate or severe periportal or periseptal lymphocytic piecemeal necrosis (n = 11). UDCA (13-15 mg/kg/d) given alone in 5 patients induced a significant decrease in biochemical cholestasis but not in ALT levels, and liver fibrosis progressed in 3 patients. Corticosteroids given alone in 6 patients induced a significant decrease in ALT, IgG, and AP levels, but none had a biochemical normalization. The patients with persistently abnormal liver tests under either UDCA or corticosteroids received both UDCA and corticosteroids. A further marked biochemical improvement was observed, and all patients became asymptomatic. We conclude that, in patients with PBC: 1) overlap syndrome with AIH is not rare; 2) flares of AIH may occur either spontaneously or under UDCA; and 3) combination of UDCA and corticosteroids is required in most patients to obtain a complete biochemical response. Overlap syndrome may represent an important and unrecognized cause of resistance to UDCA in patients with PBC.
Article
As ursodeoxycholic acid (UDCA) delays the need for transplantation, this could result in patients with more comorbid disease, therefore more likely to have a worse outcome posttransplantation. The aim of this study is to compare posttransplantation outcome in patients who received UDCA versus placebo who subsequently required a liver transplant. Data on all trial patients referred for transplantation were retrospectively collected from three randomized controlled trials of UDCA in patients with primary biliary cirrhosis (PBC). An intent-to-treat analysis was conducted with patients assigned to their original treatment allocation. UDCA and placebo groups were compared at trial entry, transplant referral, just before transplantation, and 1 month and 1 year posttransplantation. From 1987 to 1996, 37 UDCA-treated and 53 placebo patients were referred for transplantation; their age, sex, and serum bilirubin levels were similar at study entry. Immediately before transplantation, these two groups were again similar with respect to age, bilirubin level, Mayo risk score, and serum creatinine level. Posttransplantation survival rates at 1 month were 93.9% in the UDCA group and 88.4% in the placebo group, and 1 year survival rates were 90.3% and 78.4%, respectively (not significant). Posttransplantation, the two groups had similar rates of infection (53.9% v 58%); however, rejection occurred significantly less often in the UDCA group; 42.9% versus 68.8% in the placebo group (P = .04). The posttransplantation outcome of UDCA-treated patients with PBC is no different from those who were administered placebo. There is no evidence to suggest the beneficial effect of UDCA in delaying the need for transplantation is associated with a worse outcome once liver transplantation becomes necessary.
Article
Intrahepatic cholestasis of pregnancy (ICP) is a pregnancy-specific liver disorder characterized by maternal pruritus in the third trimester, raised serum bile acids and increased rates of adverse fetal outcomes. The etiology of ICP is complex and not fully understood, but it is likely to result from the cholestatic effects of reproductive hormones and their metabolites in genetically susceptible women. Equally unclear are the mechanisms by which the fetal complications occur. This article reviews the epidemiology, clinical features, diagnosis, etiology and management of ICP.
Article
Ursodeoxycholic acid (UDCA) and impaired gallbladder motility purportedly reduce biliary pain and acute cholecystitis in patients with gallstones. However, the effect of UDCA in this setting has not been studied prospectively. This issue is important, as in several countries (including the Netherlands) scheduling problems result in long waiting periods for elective cholecystectomy. We conducted a randomized, double-blind, placebo-controlled trial on effects of UDCA in 177 highly symptomatic patients with gallstones scheduled for cholecystectomy. Patients were stratified for colic number in the preceding year (<3: 32 patients; > or =3: 145 patients). Baseline postprandial gallbladder motility was measured by ultrasound in 126 consenting patients. Twenty-three patients (26%) receiving UDCA and 29 (33%) receiving placebo remained colic-free during the waiting period (89 +/- 4; median [range]: 75[4-365] days) before cholecystectomy (P = .3). Number of colics, non-severe biliary pain, and analgesics intake were comparable. A low number of prior colics was associated with a higher likelihood of remaining colic-free (59% vs. 23%, P < .001), without effects on the risk of complications. In patients evaluated for gallbladder motility, 57% were weak and 43% were strong contractors (minimal gallbladder volume > respectively < or = 6 mL). Likelihood to remain colic-free was comparable in strong and weak contractors (31% vs. 33%). In weak contractors, UDCA decreased likelihood to remain colic-free (21% vs. 47%, P = .02). In the placebo group, 3 preoperative and 2 post-cholecystectomy complications occurred. In contrast, all 4 complications in the UDCA group occurred after cholecystectomy. In conclusion, UDCA does not reduce biliary symptoms in highly symptomatic patients. Early cholecystectomy is warranted in patients with symptomatic gallstones.
Article
To assess the benefit of the UDCA-budesonide combination in association with mycophenolate mofetil (MMF) in patients with primary biliary cirrhosis (PBC) at high risk of developing cirrhosis or liver failure. Inclusion criteria for this three-year open study were: 1) suboptimal biochemical response to one-year UDCA therapy at 13-15 mg/kg/d; 2) significant interface hepatitis without cirrhosis at liver biopsy. Treatment regimen included UDCA (13-15 mg/kg/d), budesonide (6 mg/d) and MMF (1.5 g/d). All patients underwent a control biopsy at three years. Fifteen patients fulfilled the inclusion criteria. Six patients (41%) normalized biochemistries and seven (47%) had a partial but significant biochemical response, as defined by a serum bilirubin less than 17 micromol/L, alanine aminotransferase less than 70 UI/L and alkaline phosphatase less than 250 UI/L. Histological activity and fibrosis were markedly improved. Side effects were minimal or absent. Triple therapy with UDCA, budesonide and MMF may provide benefit in non-cirrhotic PBC patients with features of severe disease not responding to UDCA.